Nature Reviews Clinical Oncology最新文献_第2页

More options, more questions in the management of early relapsed and/or refractory multiple myeloma. 更多的选择，更多的问题在早期复发和/或难治性多发性骨髓瘤的管理。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-31 DOI: 10.1038/s41571-026-01191-6

Carlyn Rose Tan, Sham Mailankody

引用次数: 0

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management. adc和ICI-ADC联合的临床毒性：机制、模式和管理。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-30 DOI: 10.1038/s41571-026-01188-1

Solange Peters, Petros Grivas, Christophe Massard, Sara M Tolaney, Michel Obeid

{"title":"Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.","authors":"Solange Peters, Petros Grivas, Christophe Massard, Sara M Tolaney, Michel Obeid","doi":"10.1038/s41571-026-01188-1","DOIUrl":"https://doi.org/10.1038/s41571-026-01188-1","url":null,"abstract":"Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) have reshaped cancer therapy both as monotherapy and in combination. However, these drug classes have toxicity profiles that, despite arising from different biological mechanisms, often converge on the same organs. Given that ICI-ADC combinations are moving into earlier lines of treatment, including curative-intent settings, clinicians increasingly face overlapping pulmonary, hepatic, gastrointestinal and cutaneous adverse events with uncertain attribution, and the management of toxicities during the acute event and subsequent treatment resumption and the management of rechallenge after toxicity resolution remain variable. In this Review, we propose a unified, mechanism-informed framework that links three interacting layers: immune activation, payload cytotoxicity and payload-independent effects (from target, platform and host-related determinants). We compare organ-level patterns across major payload classes, highlight consistent organ signatures and provide practical algorithms for evaluation, initial management and treatment resumption in patients receiving ADC monotherapy or ICI-ADC combinations. Finally, we propose minimum reporting standards to harmonize toxicity phenotyping and enable cross-trial comparisons, biomarker discovery and the development of safer regimens.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-escalation trials in multiple myeloma: past, present and future. 多发性骨髓瘤的降级试验：过去，现在和未来。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-29 DOI: 10.1038/s41571-026-01186-3

Hira Mian, Luciano J Costa, Mohamad Mohty, Alfred Garfall, S Vincent Rajkumar

{"title":"De-escalation trials in multiple myeloma: past, present and future.","authors":"Hira Mian, Luciano J Costa, Mohamad Mohty, Alfred Garfall, S Vincent Rajkumar","doi":"10.1038/s41571-026-01186-3","DOIUrl":"https://doi.org/10.1038/s41571-026-01186-3","url":null,"abstract":"De-escalation of therapy constitutes a new phase in the development of therapeutic approaches for patients with multiple myeloma (MM) and is aimed at maintaining durable disease control while reducing the toxicity and burden associated with prolonged treatment. Given that increasingly effective agents, including immunotherapies, are now used earlier in the course of MM, we must assess not only how much therapy is needed to enable a clinical response but also how much is required to sustain it. In this Review, we synthesize emerging evidence supporting multiple de-escalation strategies, including dose and schedule modification, withdrawal of individual agents from multidrug regimens, fixed-duration approaches with treatment-free intervals, minimal residual disease-adapted strategies, omission of autologous stem cell transplantation and single infusion of chimeric antigen receptor T cells. We highlight how contemporary trials are beginning to define the patient populations and treatment components most amenable to de-escalation while exposing ongoing uncertainties and challenges, including those relating to monitoring strategies, re-treatment criteria and feasibility. Finally, we discuss methodological and implementation challenges including end point selection, clinical trial design, integration of correlative translational research, funding models and the involvement of key stakeholders required to translate de-escalation approaches from concept to a clinical trial and, eventually, routine clinical practice.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harm. 电子烟、吸烟和肺癌风险：关于持续危害的一些证据。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-28 DOI: 10.1038/s41571-026-01192-5

Peter G Shields

引用次数: 0

Towards liquid biopsy-based analysis of antitumour immunity. 基于液体活检的抗肿瘤免疫分析。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-24 DOI: 10.1038/s41571-026-01181-8

Klaus Pantel, Doryan Masmoudi, Catherine Alix-Panabières

{"title":"Towards liquid biopsy-based analysis of antitumour immunity.","authors":"Klaus Pantel, Doryan Masmoudi, Catherine Alix-Panabières","doi":"10.1038/s41571-026-01181-8","DOIUrl":"https://doi.org/10.1038/s41571-026-01181-8","url":null,"abstract":"Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune responses, repeated tumour biopsy is invasive and rarely feasible for monitoring dynamic immune responses over time. Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease. These liquid biopsy-based approaches cannot provide spatial information on the tumour immune microenvironment and tumour-derived material can be highly diluted in the circulation, yet they offer a unique opportunity to monitor systemic immune dynamics, anticipate responses to immunotherapies and detect emerging resistance to treatment. Thus, blood-based analyses might complement tumour tissue analysis. In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does OptiTROP-Lung05 open a new frontier for first-line ADC-ICI combinations in NSCLC? OptiTROP-Lung05是否为非小细胞肺癌一线ADC-ICI联合治疗开辟了新领域？

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-20 DOI: 10.1038/s41571-026-01183-6

Myung-Ju Ahn

引用次数: 0

Second-line 177Lu-edotreotide shows promise in GEP NETs 二线177Lu-edotreotide在GEP NETs中显示出希望

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-16 DOI: 10.1038/s41571-026-01187-2

Diana Romero

引用次数: 0

Crossover does not confound, it informs: 177lutetium-PSMA-617 as an example 交叉不会混淆，它通知：177lutetium-PSMA-617为例

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-16 DOI: 10.1038/s41571-026-01182-7

Martin W. Schoen, Tito Fojo, Johann de Bono

引用次数: 0

The future of ciltacabtagene autoleucel in multiple myeloma has just begun 西塔卡他基自体乙醇治疗多发性骨髓瘤的未来才刚刚开始。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-14 DOI: 10.1038/s41571-026-01184-5

Maximilian Merz, Nico Gagelmann

引用次数: 0

Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma 西他tagene autoeucel预示着固定时间治疗骨髓瘤的到来。

IF 94.6 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-07-14 DOI: 10.1038/s41571-026-01185-4

Ghulam Rehman Mohyuddin, Edward R. Scheffer Cliff, Rajshekhar Chakraborty

引用次数: 0